Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

How to Assess New Technology

Wednesday, June 14
1:30 pm – 2:30 pm
Room 45



Thomas S. Harper, Ph.D.

Senior Manager
Plante Moran




Creating robust product pipelines is a top priority for most global orthopaedic device companies, yet our industry’s commercial success rate for new product launches remains less than 20%. Traditionally one of the largest contributors to the less-than-stellar success rate is failure in the very first steps of the development process: a new technology assessment. We will examine the ways that companies address challenges associated with new technology assessments, and some of the key lessons learned.


Attendee Takeaways

  1. Understanding of how peers are addressing challenges associated with new technology assessment
  2. A solid framework to balance clinical, regulatory and technical risk with market needs
  3. Best practices and trends to ensure successful product assessments and launches in the future 


Mr. Harper has more than 25 years of experience in sales and marketing management, product commercialization, due diligence and business development in the medical device industry. His expertise spans a broad range of healthcare products, and he has successfully led the global commercialization of implantable, disposable, reusable and capital equipment medical devices for a variety of companies, ranging from early stage start-up to large global life sciences companies. During his career, Mr. Harper has assisted or led the global launch of 60+ medical device products while leading teams at Johnson & Johnson, Cardinal Health and over 20 global medical device client companies. 

Helpful links: Executives Warn of Paradigm Shift in R&D Spend | Integrating Internal Strategies to Impact a Successful Product Launch